NCT05673577View on ClinicalTrials.gov

Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

October 31, 2025

Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
DRUG

Camrelizumab+cetuximab+chemotherapy

"Camrelizumab: 200mg vgtt q3w, 3 weeks as a cycle; Cetuximab first dose 400mg/m2, vgtt, following by 250 mg/m2 after first dose, qw, 3 weeks as a cycle; albumin paclitaxel: 125mg/m2, vgtt, d1, 8, q3w，for up to 6 cycles; cisplatin: 75mg/m2, vgtt，d1，q3w, for up to 6 cycles;~Then, in maintenance therapy, Camrelizumab: 200mg vgtt q2w; Cetuximab 500mg/m2, vgtt q2w until intolerable toxicity or disease progression"

Trial Locations (1)

Unknown

Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER